US EditionDr. Tejal Aslesh Tailor: Biotech Innovation Without Access Isn’t Healthcare at All
3 Articles
3 Articles
Dr. Tejal Aslesh Tailor: Biotech Innovation Without Access Isn’t Healthcare at All
In the United States, many people are forced to resort to platforms like GoFundMe to pay for life-saving treatments, even as the nation’s biotech innovation leads across the globe. Take Zolgensma, a gene therapy for spinal muscular atrophy (SMA), which costs nearly $2 million per patient. Despite technological breakthroughs accelerating rapidly, access to these treatments is often not covered by insurance and still remains widely inaccessible. T…
The Ministry of Health estimates that it will spend R$959 million over the next 2 years on the acquisition of doses of Zolgensma, a drug intended for the treatment of SMA (Spinal Muscular Atrophy) and considered the most expensive in the world. The doses will be given to children up to 6 months of age diagnosed with SMA type 1, the most severe case of the disease, who do not receive invasive mechanical ventilation for more than 16 hours a day. T…
Drug application in the public network will be restricted to babies up to six months with the most serious type of disease; the Ministry of Health estimates that 137 people are expected to spend R$ 959 million in the next two years on the purchase of Zolgensma, considered the most expensive medicine in the world. The remedy is used in the treatment of spinal muscular atrophy (AME), a disease that, according to government data, affects 1 to every…
Coverage Details
Bias Distribution
- 100% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
